ArticleFrontiers in oncology2023
The incidence and mortality of lung cancer in China: a trend analysis and comparison with G20 based on the Global Burden of Disease Study 2019.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023.Frontiers in oncology · 2024Pooled it
- Development of a Prognostic Survival Risk Score for Lung Cancer Patients With Type 2 Diabetes Mellitus: A Territory-Wide Retrospective Cohort Study.Cancer medicine · 2026Article
- Trends in lung cancer incidence and mortality and the potential for overdiagnosis associated with computed tomography screening across 21 countries on six continents.Journal of thoracic disease · 2026Article
- Effects of Information Source Characteristics on Trust and Health Information Behaviours Among Individuals with Different Levels of Cyberchondria.Behavioral sciences (Basel, Switzerland) · 2026Article
- Diverging Trajectories of Lung Cancer Burden in China, Japan, and South Korea: A Comparative Risk Assessment from the Global Burden of Disease Study 1990-2021.Thoracic cancer · 2026Article
- Bone morphogenetic protein 5 as a potential diagnostic and prognostic biomarker in lung adenocarcinoma.Translational cancer research · 2026Article
- Global, regional, and national trends in burden of lung cancer and chronic obstructive pulmonary disease and associated risk factors, 1990-2021: results from the global burden of disease study 2021.NPJ primary care respiratory medicine · 2026Article
- Publication Characteristics and Reporting Quality of GBD-Derived Burden of Disease Studies: A Cross-Sectional Analysis of Lung Cancer.Journal of evidence-based medicine · 2026Article
- [Expression of S100P in Lung Adenocarcinoma and Its Clinical Significance].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Article
- AI-MDT: an automatic and intelligent multidisciplinary team consultations platform for lung cancer diagnosis.Journal of cancer research and clinical oncology · 2026Article
- Burden of atrial fibrillation and atrial flutter attributable to smoking in the G20: Trends from 1990 to 2021 and predictions for 2022 to 2050: A secondary dataset analysis of the Global Burden of Disease (GBD) 2021.Tobacco induced diseases · 2026Article
- Angelicin Inhibits NSCLC Tumor Growth via the Inhibition of Cancer-Associated Fibroblasts.Combinatorial chemistry & high throughput screening · 2026Article
- Analysis and prediction of the burden of lung cancer attributable to diet low in fruits in China and the global from 1990 to 2021.PloS one · 2026Article
- Exploring the Impact of TP53 Mutation and Wild-Type Status on the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Article
- Disease burden and trends of bladder cancer in the world and BRICS from 1990 to 2021 and its projection until 2036: analysis based on the global burden of disease study 2021.Discover oncology · 2025Article
- Risk factors of bone metastasis in lung adenocarcinoma.BMC pulmonary medicine · 2025Article
- Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors.Cancer innovation · 2025Article
- Tracheal, bronchus, and lung cancer among older adults: thirty-year global burden trends, precision medicine breakthroughs, and lingering barriers.BMC cancer · 2025Article
- Mapping the patent landscape of TROP2-targeted biologics through deep learning.Nature biotechnology · 2025Article
- Dexmedetomidine combined with propofol improves hemodynamic stability and recovery in elderly patients undergoing thoracoscopic lung cancer resection.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is a significant health concern in China. There is limited available data of its burden and trends. This study aims to evaluate the trends of lung cancer across different age groups and genders in China and the Group of Twenty (G20) countries, explore the risk factors, and predict the future trends over a 20-year period. Methods: The data were obtained from the GBD study 2019. The number of cases, age standardized rate (ASR), and average annual percentage changes (AAPC) were used to estimate the trend in lung cancer by age, gender, region and risk factor. The trend of lung cancer was predicted by autoregressive integrated moving average (ARIMA) model by the "xtarimau" command. The joinpoint regression analysis was conducted to identify periods with the highest changes in incidence and mortality. Additionally, the relationship between AAPCs and socio-demographic index (SDI) was explored. Results: From 1990 to 2019, both the incidence and mortality of lung cancer in China and G20 significantly increased, with China experiencing a higher rate of increase. The years with the highest increase in incidence of lung cancer in China were 1998-2004 and 2007-2010. Among the G20 countries, the AAPC in incidence and mortality of lung cancer in the Republic of Korea was the highest, followed closely by China. Although India exhibited similarities, its AAPC in lung cancer incidence and mortality rates was lower than that of China. The prediction showed that the incidence in China will continue to increase. In terms of risk factors, smoking was the leading attributable cause of mortality in all countries, followed by occupational risk and ambient particulate matter pollution. Notably, smoking in China exhibited the largest increase among the G20 countries, with ambient particulate matter pollution ranking second. Conclusion: Lung cancer is a serious public health concern in China, with smoking and environmental particulate pollution identified as the most important risk factors. The incidence and mortality rates are expected to continue to increase, which places higher demands on China's lung cancer prevention and control strategies. It is urgent to tailor intervention measures targeting smoking and environmental pollution to contain the burden of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.